Real-World Experience Study of an Active Drug For the Treatment of Endometriosis in Canada

Brief summary

The objective of this study is to evaluate real-world effectiveness of an active drug in Canadian women with endometriosis.

Observational study

100 patients
Protocol ID:
Observational model:
Time perspective:


Eligibility criteria

Participant attributes:


From 18 Years to 50 Years.

Inclusion Criteria:

- Prescribed elagolix as part of standard treatment

- Naive to elagolix prior to starting this study or have stopped taking elagolix for 2
months prior to the start of this study

- Symptomatic endometriosis (clinically or surgically diagnosed) including currently
experiencing dysmenorrhea

- Has provided written informed consent allowing the use of their data for the study

Exclusion Criteria:

- Did not consent

- Cannot fill out questionnaires

- Prescribed elagolix for a period of 1 or 2 months only

- Post-menopausal (naturally or surgically)

- Symptomatic uterine fibroid(s)

- Had medical treatment for uterine fibroids (any length of treatment)

All the cities where the clinical studies are located

Calgary - T3M 1M4
Edmonton - T5T 1L6
Vancouver - V6H 2N9
St. John's - A1A 4Y3
Halifax - B3K 6R8
Hamilton - L8S 4K1
London - N5X 2N7
Ottawa - K1H 8L6
Sudbury - P3A 1W8
Toronto - M4N 3M5
Toronto - M5B 1W8
Gatineau - J8P 7H2
Lasalle - H8N 1T9
Longueuil - J4N 1C2
Montreal - H1T 2M4
Montreal - H3T 1E2
Montréal - H4A 3T2
Québec - G1V 4G2

More information about this study